Abstract B6: A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5‐days‐on/9‐days‐off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck

2009 ◽  
Author(s):  
Tanguy Seiwert ◽  
Suzanne Swann ◽  
Hazel Kurz ◽  
Peter Bonate ◽  
Stewart McCallum ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Head And Neck ◽  
Phase Ii ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Squamous Cell Cancer ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Efficacy And Safety

scholarly journals Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer

2017 ◽  
Vol 22 (7) ◽  
pp. 782 ◽  
Author(s):  
Marco Siano ◽  
Francesca Molinari ◽  
Vittoria Martin ◽  
Nicolas Mach ◽  
Martin Früh ◽  
...  
Keyword(s):  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Advanced Head ◽  
Multicenter Phase ◽  
Neck Squamous Cell Cancer
Sign in / Sign up

Export Citation Format

Share Document